Skip to content

Community-Based Comprehensive Intervention to Chronic Obstructive Pulmonary Disease in Guangdong, China

The Study on Prevalence and Comprehensive Intervention of COPD in China

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-PRC-09000532
Enrollment
Unknown
Registered
2009-09-19
Start date
2002-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Group A:Only usual care will be performed in the control community (CC).
Group B:In the intervention community (IC), the special comprehensive interventions will be delivered to three stratifications including general population, high-risk group and COPD patients besides u

Sponsors

Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male and female aged of 40 years or older; 2. Written informed consent obtained; 3. Residents in these two communities, Guangzhou city; 4. Residents received a baseline screening survey in September 2002; 5. Ability to perform an acceptable spirometry and complete questionnaires.

Exclusion criteria

Exclusion criteria: 1. Accompanying with active tuberculosis, asthma or obvious bronchiectasisa, cystic fibrosis, interstitial lung disease, or pulmonary thromboembolic disease; 2. Accompanying with malignant tumor; 3. History of thoracotomy with pulmonary resection; 4. Uncontrolled or very serious cardiovascular, endocrine, blood, mental diseases, or nervous system disorders; 5. Uncontrolled condition with COPD exacerbation level; 6. Participating in any other investigational drug study within the trial period; 7. Bad compliance, judged by the investigators, not to be appropriate for inclusion in the trial; 8. Life expectancy less than 4 years; 9. Others situation that may have influence on the results of the study or the patient's ability to participate in the study.

Design outcomes

Primary

MeasureTime frame
Annual decline in pre-bronchodilator FEV;

Secondary

MeasureTime frame
Improvements in awareness of COPD and related risk;Annual decline in pre-bronchodilators FEV1 between smokers and no smokers;Quality of life assessment (scores of SF-12);Changes of related risk factors from baseline, i.e;Comparisons of the incidence rate and case fatality;

Contacts

Public ContactPixin Ran
pxran@gzhmc.edu.cn+86 13922765811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026